Ark Biosciences Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Shanghai China (2014)

Organization Overview

First Clinical Trial
2014
NCT02297594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Ark Biosciences | Ark Biosciences Inc. | Ark Biosciences Pty Ltd. | info@arkbiosciences.com | Shanghai Ark Biopharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

Ziresovir (8 trials)

Drugs in Phase 2 Trials (1)

ak3280 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 3)

Respiratory Syncytial Virus Infections (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 2